{
    "organizations": [],
    "uuid": "2a3d8f4674733a223d4ce46a077ebafdf2b9cd89",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-redx-pharma-says-temporarily-inter/brief-redx-pharma-says-temporarily-interrupting-patient-accrual-to-phase-1-2a-clinical-study-for-porcupine-inhibitor-idUSASO0002S4",
    "ord_in_thread": 0,
    "title": "Redx Pharma says temporarily interrupting patient accrual to phase 1/2a clinical study for porcupine inhibitor​",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "March 29 (Reuters) - Redx Pharma Plc:\n* RXC004 CLINICAL TRIAL UPDATE * ‍TEMPORARILY INTERRUPTING PATIENT ACCRUAL TO ITS PHASE 1/2A CLINICAL STUDY FOR PORCUPINE INHIBITOR, RXC004​\n* CURRENT INTENTION TO PROPOSE PROTOCOL AMENDMENT THAT ENABLES DOSE- ESCALATION TO RE-START AT SIGNIFICANTLY LOWER DOSE LEVELS​ Further company coverage:\n ",
    "published": "2018-03-29T14:57:00.000+03:00",
    "crawled": "2018-03-30T13:24:04.008+03:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "march",
        "reuters",
        "redx",
        "pharma",
        "plc",
        "rxc004",
        "clinical",
        "trial",
        "update",
        "interrupting",
        "patient",
        "accrual",
        "phase",
        "clinical",
        "study",
        "porcupine",
        "inhibitor",
        "current",
        "intention",
        "propose",
        "protocol",
        "amendment",
        "enables",
        "escalation",
        "significantly",
        "lower",
        "dose",
        "company",
        "coverage"
    ]
}